Homology Medicines, Inc. (FIXX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 2.8500 |
| Open | 2.8700 |
| Bid | 2.6400 x 1000 |
| Ask | 3.2000 x 1200 |
| Day's Range | 2.6100 - 2.8700 |
| 52 Week Range | 1.3000 - 8.9000 |
| Volume | |
| Avg. Volume | 375,532 |
| Market Cap | 157.735M |
| Beta (5Y Monthly) | -0.46 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.7340 |
| Earnings Date | Mar 09, 2022 - Mar 14, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.14 |
- Benzinga
Homology Medicines Announces Preclinical Gene Therapy Candidate For Genetic Storage Disorder
Homology Medicines Inc (NASDAQ: FIXX) announced the details of HMI-204, its optimized, in vivo, one-time gene therapy candidate for metachromatic leukodystrophy (MLD). Following a single I.V. administration in the MLD animal model, the candidate crossed the blood-brain barrier to the central nervous system (CNS) and reached key peripheral organs involved in MLD. Also Read: Homology Medicines Stock Plunges After FDA Clinical Hold On Gene Therapy Trial. Data demonstrated biodistribution to brain r
- GlobeNewswire
Homology Medicines Announces Optimized, In Vivo Gene Therapy Candidate for the Treatment of Metachromatic Leukodystrophy
- Candidate Showed Ability to Target Central Nervous System and Peripheral Organs Following a Single I.V. Administration in MLD Model, a Key Differentiator from Available Treatments and Product Candidates - - Data Demonstrated Biodistribution to Brain Regions and Multiple Cell Types - - Optimizations Included Significant Improvements in Expression, Productivity and Packaging - - Homology Seeks Partner to Advance Development Candidate - BEDFORD, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Homology M
- Simply Wall St.
Homology Medicines (NASDAQ:FIXX) investors are sitting on a loss of 87% if they invested three years ago
Homology Medicines, Inc. ( NASDAQ:FIXX ) shareholders should be happy to see the share price up 29% in the last...
